ArticleBMC cancer2022

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.

Kai Shang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.